Gene Therapy with Viral Vectors

Annual Review of Pharmacology and Toxicology

Volumn 43, Issue , 2003, Pages 413-439

  Kootstra, Neeltje A ^a   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

AAV; Adenovirus; HSV; Lentivirus; Retrovirus

Indexed keywords

ADENOVIRUS VECTOR; CIS ACTING ELEMENT; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; VIRUS DNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; COMBINED IMMUNODEFICIENCY; DNA INTEGRATION; GENE THERAPY; GENETIC DISORDER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROVIRUS; REVERSE TRANSCRIPTION; REVIEW; SPUMA VIRUS; T LYMPHOCYTE; TRANSGENE; VARICELLA ZOSTER VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; VIRUS;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; SIMPLEXVIRUS; SPUMAVIRUS; UNIDENTIFIED RETROVIRUS;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; VIRUSES;

EID: 0038764055     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.43.100901.140257     Document Type: Review

References (140)

1. Muzyczka N, Berns KI. 2001. Parvoviridae: the viruses and their replication. See Ref. 140, 2:2327-60
2. Hermonat PL, Muzyczka N. 1984. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. USA 81:6466-70
3. Samulski RJ, Chang LS, Shenk T. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63:3822-28
4. Xiao X, Li J, Samulski RJ. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:2224-32
5. Graham FL, Smiley J, Russell WC, Naim R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74
6. Li J, Samulski RJ, Xiao X. 1997. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71:5236-43
7. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-45
8. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77
9. Summerford C, Bartlett JS, Samulski RJ. 1999. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82
10. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM. 1997. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71:6823-33
11. Chiorini JA, Kim F, Yang L, Kotin RM. 1999. Cloning and characterization of adeno-associated virus type 5. J. Virol. 73:1309-19
12. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, et al. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76:791-801
13. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, et al. 2000. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74:3852-58
14. Handa A, Muramatsu S, Qiu J, Mizukami H, Brown KE. 2000. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 81:2077-84
15. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, et al. 2000. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97:3428-32
16. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. 1999. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat. Biotechnol. 17:181-86
17. Rabinowitz JE, Xiao W, Samulski RJ. 1999. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265:274-85
18. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, et al. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-47
19. Ferrari FK, Samulski T, Shenk T, Samulski RJ. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:3227-34
20. Malik AK, Monahan PE, Allen DL, Chen BG, Samulski RJ, Kurachi K. 2000. Kinetics of recombinant adeno-associated virus-mediated gene transfer. J. Virol. 74:3555-65
21. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, et al. 1998. The kinetics of rAAV integration in the liver. Nat. Genet. 19:13-15
22. Russell DW, Miller AD, Alexander IE. 1994. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 91:8915-19
23. Alexander IE, Russell DW, Miller AD. 1994. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J. Virol. 68:8282-87
24. Russell DW, Alexander IE, Miller AD. 1995. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 92:5719-23
25. Kearns WG, Afione SA, Fulmer SB, Pang MC, Erikson D, et al. 1996. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. 3:748-55
26. Duan D, Yue Y, Yan Z, Engelhardt JF. 2000. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 6:595-98
27. Sun L, Li J, Xiao X. 2000. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6:599-602
28. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. 1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1574-83
29. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. 1999. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92:67-75
30. Goff SP. 2001. Retroviridae: the retroviruses and their replication. See Ref. 140, 2:1871-940
31. Sodroski J, Patarca R, Rosen C, Wong-Staal F, Haseltine W. 1985. Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science 229:74-77
32. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, et al. 1986. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320:367-71
33. Malim MH, Hauber J, Fenrick R, Cullen BR. 1988. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335:181-83
34. Rethwilm A, Erlwein O, Baunach G, Maurer B, ter Meulen V. 1991. The transcriptional transactivator of human foamy virus maps to the bel 1 genomic region. Proc. Natl. Acad. Sci. USA 88:941-45
35. Mann R, Mulligan RC, Baltimore D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-59
36. Mann R, Baltimore D. 1985. Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J. Virol. 54:401-7
37. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. 1994. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83:43-50
38. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, et al. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83:3194-98
39. Danos O, Mulligan RC. 1988. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85:6460-64
40. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-67
41. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-75
42. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-80
43. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72:8150-57
44. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-22
45. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. 2000. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173-85
46. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-71
47. Kaul M, Yu H, Ron Y, Dougherty JP. 1998. Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology 249:167-74
48. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. 1999. A packaging cell line for lentivirus vectors. J. Virol. 73:576-84
49. Klages N, Zufferey R, Trono D. 2000. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2:170-76
50. Heinkelein M, Schmidt M, Fischer N, Moebes A, Lindemann D, et al. 1998. Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J. Virol. 72:6307-14
51. Erlwein O, Bieniasz PD, McClure MO. 1998. Sequences in pol are required to transfer of human foamy virus-based vectors. J. Virol. 72:5510-16
52. Goepfert PA, Shaw KL, Ritter GD Jr, Mulligan MJ. 1997. A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum. J. Virol. 71:778-84
53. Miller AD, Law MF, Verma IM. 1985. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol. Cell. Biol. 5:431-37
54. Cone RD, Mulligan RC. 1984. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc. Natl. Acad. Sci. USA 81:6349-53
55. Spector DH, Wade E, Wright DA, Koval V, Clark C, et al. 1990. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J. Virol. 64:2298-308
56. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. 1996. Efficient gene transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93:11382-88
57. Miyoshi H, Takahashi M, Gage FH, Verma IM. 1997. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA 94:10319-23
58. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. 1997. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17:314-17
59. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. 1999. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283:682-86
60. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, et al. 2001. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10:2109-21
61. Desmaris N, Bosch A, Salaun C, Petit C, Prevost MC, et al. 2001. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol. Ther. 4:149-56
62. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. 2001. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19:225-30
63. Stitz J, Buchholz CJ, Engelstadter M, Uckert W, Bloemer U, et al. 2000. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 273:16-20
64. Goemer M, Horn PA, Peterson L, Kurre P, Storb R, et al. 2001. Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood 98:2065-70
65. Zack JA, Haislip AM, Krogstad P, Chen IS. 1992. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J. Virol. 66:1717-25
66. Schuitemaker H, Kootstra NA, Fouchier RA, Hooibrink B, Miedema F. 1994. Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J. 13:5929-36
67. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. 1997. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71:6641-49
68. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. 1998. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95:595-604
69. Korin YD, Zack JA. 1998. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72:3161-68
70. 1 phase of the cell cycle. J. Virol. 74:1712-17
71. Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, et al. 1997. Human foamy virus reverse transcription that occurs late in the viral replication cycle. J. Virol. 71:7305-11
72. Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, Linial ML. 1996. Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science 271:1579-82
73. Miller DG, Adam MA, Miller AD. 1990. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10:4239-42
74. Roe T, Reynolds TC, Yu G, Brown PO. 1993. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12:2099-108
75. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, et al. 1992. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA 89:6580-84
76. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, et al. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365:666-69
77. Gallay P, Hope T, Chin D, Trono D. 1997. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA 94:9825-30
78. Bouyac-Bertoia M, Dvorin JD, Fouchier RA, Jenkins Y, Meyer BE, et al. 2001. HIV-1 infection requires a functional integrase NLS. Mol. Cell 7:1025-35
79. Schliephake AW, Rethwilm A. 1994. Nuclear localization of foamy virus Gag precursor protein. J. Virol. 68:4946-54
80. Bieniasz PD, Weiss RA, McClure MO. 1995. Cell cycle dependence of foamy retrovirus infection. J. Virol. 69:7295-99
81. Mergia A, Chari S, Kolson DL, Goodenow MM, Ciccarone T. 2001. The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology 280:243-52
82. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. 2000. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74:4839-52
83. Poeschla E, Gilbert J, Li X, Huang S, Ho A, Wong-Staal F. 1998. Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J. Virol. 72:6527-36
84. Schnell T, Foley P, Wirth M, Munch J, Uberla K. 2000. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 11:439-47
85. Poeschla EM, Wong-Staal F, Looney DJ. 1998. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4:354-57
86. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, et al. 1999. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6:1808-18
87. Berkowitz RD, Ilves H, Plavec I, Veres G. 2001. Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. Virology 279:116-29
88. Browning MT, Schmidt RD, Lew KA, Rizvi TA. 2001. Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions. J. Virol. 75:5129-40
89. Shenk TE. 2001. Adenoviridae: the viruses and their replication. See Ref. 140, pp. 2265-300
90. Berkner KL, Sharp PA. 1983. Generation of adenovirus by transfection of plasmids. Nucleic Acids Res. 11:6003-20
91. Haj-Ahmad Y, Graham FL. 1986. Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J. Virol. 57:267-74
92. Wang Q, Finer MH. 1996. Second-generation adenovirus vectors. Nat. Med. 2:714-16
93. Yeh P, Dedieu JF, Orsini C, Vigne E, Denefle P, Perricaudet M. 1996. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-65
94. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93:13565-70
95. Parks RJ, Bramson JL, Wan Y, Addison CL, Graham FL. 1999. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J. Virol. 73:8027-34
96. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-23
97. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-19
98. Zabner J, Freimuth P, Puga A, Fabrega A, Welsh MJ. 1997. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J. Clin. Invest. 100:1144-49
99. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. 1996. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 14:1570-73
100. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, et al. 1998. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58:5738-48
101. Harari OA, Wickham TJ, Stocker CJ, Kovesdi I, Segal DM, et al. 1999. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther. 6:801-7
102. Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT. 2000. Ecto-domain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74:6875-84
103. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, et al. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-13
104. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. 1998. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72:1844-52
105. Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. 2000. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7:13-19
106. Chiu CY, Mathias P, Nemerow GR, Stewart PL. 1999. Structure of adenovirus complexed with its internalization receptor, alpha v beta5 integrin. J. Virol. 73:6759-68
107. Zabner J, Chillon M, Grunst T, Moninger TO, Davidson BL, et al. 1999. A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. J. Virol. 73:8689-95
108. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. 2000. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 74:2567-83
109. Chillon M, Bosch A, Zabner J, Law L, Armentano D, et al. 1999. Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J. Virol. 73:2537-40
110. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. 1998. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. USA 95:11377-82
111. Lieber A, Steinwaerder DS, Carlson CA, Kay MA. 1999. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. 73:9314-24
112. Zheng C, Baum BJ, Iadarola MJ, O'Connell BC. 2000. Genomic integration and gene expression by a modified adenoviral vector. Nat. Biotechnol. 18:176-80
113. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, et al. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71:8798-807
114. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. 1999. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10:965-76
115. Marshall E. 1999. Gene therapy death prompts review of adenovirus vector. Science 286:2244-45
116. Morsy MA, Gu M, Motzel S, Zhao J, Lin J, et al. 1998. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95:7866-71
117. Roizman B, Knipe DM. 2001. Herpes simplex viruses and their replication. See Ref. 140, pp. 2399-460
118. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, et al. 1996. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. USA 93:11319-20
119. Samaniego LA, Neiderhiser L, DeLuca NA. 1998. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72:3307-20
120. Spaete RR, Frenkel N. 1982. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30:295-304
121. Kwong AD, Frenkel N. 1985. The herpes simplex virus amplicon. IV. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes. Virology 142:421-25
122. Geller AI, Breakefield XO. 1988. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241:1667-69
123. Cunningham C, Davison AJ. 1993. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 197:116-24
124. Saeki Y, Ickikawa T, Saeki A, Chiocca EA, Tobler K, et al. 1998. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 9:2787-94
125. Stavropoulos TA, Strathdee CA. 1998. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J. Virol. 72:7137-43
126. Anderson DB, Laquerre S, Ghosh K, Ghosh HP, Goins WF, et al. 2000. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J. Virol. 74:2481-87
127. Laquerre S, Anderson DB, Stolz DB, Glorioso JC. 1998. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 72:9683-97
128. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-72
129. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-75
130. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, et al. 1995. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475-80
131. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, et al. 1995. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med. 1:1017-23
132. Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, et al. 1996. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3:179-83
133. Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, et al. 1998. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4:775-80
134. Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, et al. 2002. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat. Med. 8:423-25
135. May C, Rivella S, Callegari J, Heller G, Gaensler KM, et al. 2000. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406:82-86
136. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, et al. 2001. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294:2368-71
137. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, et al. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-73
138. Consiglio A, Quattrini A, Martino S, Bensadoun JC, Dolcetta D, et al. 2001. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7:310-16
139. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, et al. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24:257-61
140. Knipe DM, Howley PM, eds. 2001. Fields' Virology, Vol. 2. Philadelphia: Lippincott, Williams & Wilkins